"[FEBC1541E5CA]" . "IN - Indick\u00E1 republika" . . . "6"^^ . . . "Journal of Postgraduate Medicine" . "Use of recombinant factor VIIa for emergency reversal of anticoagulation" . "1" . "RIV/00216208:11120/07:00000882!RIV09-MSM-11120___" . . "1"^^ . "456962" . "Pou\u017E\u00EDt\u00ED rekombinantn\u00EDch faktor\u016F VIIa v pohotovostn\u00EDm obratu antikoagulace"@cs . "Existuj\u00ED pouze omezen\u00E1 data o pou\u017Eit\u00ED aktivovan\u00E9ho rekombinantn\u00EDho faktoru VII (rFVIIa) u pacient\u016F na antikoagula\u010Dn\u00ED terapii, u nich\u017E je pot\u0159ebn\u00FD zvrat t\u00E9to antikoagulace. C\u00EDlem pr\u00E1ce bylo identifikovat pacienty, kter\u00FDm byl pod\u00E1n rFVIIa jako sou\u010D\u00E1st emergentn\u00ED l\u00E9\u010Dby ke zlep\u0161en\u00ED hemost\u00E1zy. Data byla z\u00EDsk\u00E1na z mezin\u00E1rodn\u00EDho kontrolovan\u00E9ho registru haemostasis.com. (registr obsahuje data hl\u00E1\u0161en\u00E1 l\u00E9ka\u0159i, kte\u0159\u00ED se rozhodli pou\u017E\u00EDt rFVIIa ke stav\u011Bn\u00ED krv\u00E1cen\u00ED v emergentn\u00ED klinick\u00E9 situaci). Bylo nalezeno 19 pacient\u016F, kter\u00FDm byl pod\u00E1n rFVIIa (medi\u00E1n d\u00E1vky: 87.35 microg/kg; rozp\u011Bt\u00ED: 20.0-106.0 microg/kg), u v\u0161ech t\u011Bchto pacient\u016F selhala tradi\u010Dn\u00ED antidota a krevn\u00ED produkty. Po pod\u00E1n\u00ED se krv\u00E1cen\u00ED zastavilo u 10, podstatn\u011B sn\u00ED\u017Eilo u 5 a zpomalilo u zb\u00FDvaj\u00EDc\u00EDch 3 pacient\u016F. Po\u017Eadavky na krevn\u00ED produkty a krystaloidy/koloidy se po pod\u00E1n\u00ED rFVIIa sn\u00ED\u017Eily ( P < 0.05)"@cs . . "3"^^ . "Culic, S." . . "53" . "There is limited data regarding the use of activated recombinant factor VII (rFVIIa) in anticoagulated patients requiring reversal. Aims: To identify and describe characteristics of subjects who received rFVIIa as part of emergency treatment aimed at improving hemostasis. Settings and Design: Data was obtained from an international peer-reviewed registry haemostasis.com. This registry contains data reported by physicians, who had elected to use rFVIIa to control bleeding in an emergency clinical situation. The contributors' approval for inclusion in the study was obtained and they were requested to validate and update information. Materials and Methods: Database review of cases receiving rFVIIa to manage bleeding coherent with the use of anticoagulant therapy. Statistical Analysis: The Wilcoxon signed rank test was used to compare requirements for blood products and crystalloids/colloids during the 24h preceding and following rFVIIa administration, as well as changes in the levels of clotting fac"@en . "anticoagulation therapy; bleeding; recombinant activated factor VII; rFVIIa"@en . "Use of recombinant factor VIIa for emergency reversal of anticoagulation"@en . "000244368200010" . "Use of recombinant factor VIIa for emergency reversal of anticoagulation"@en . "Use of recombinant factor VIIa for emergency reversal of anticoagulation" . "11120" . . "Ingerslev, J." . . . "RIV/00216208:11120/07:00000882" . "0022-3859" . "Van\u011Bk, Tom\u00E1\u0161" . . "Pou\u017E\u00EDt\u00ED rekombinantn\u00EDch faktor\u016F VIIa v pohotovostn\u00EDm obratu antikoagulace"@cs . . . . "S" . "There is limited data regarding the use of activated recombinant factor VII (rFVIIa) in anticoagulated patients requiring reversal. Aims: To identify and describe characteristics of subjects who received rFVIIa as part of emergency treatment aimed at improving hemostasis. Settings and Design: Data was obtained from an international peer-reviewed registry haemostasis.com. This registry contains data reported by physicians, who had elected to use rFVIIa to control bleeding in an emergency clinical situation. The contributors' approval for inclusion in the study was obtained and they were requested to validate and update information. Materials and Methods: Database review of cases receiving rFVIIa to manage bleeding coherent with the use of anticoagulant therapy. Statistical Analysis: The Wilcoxon signed rank test was used to compare requirements for blood products and crystalloids/colloids during the 24h preceding and following rFVIIa administration, as well as changes in the levels of clotting fac" . .